Related Experiment Video
Updated: Jun 1, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Prasugrel, a new medicine for preventing blockages in the arteries
Zhi-Mei Wang1, Jian Zhao, Gang Xu
1School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, People's Republic of China.
Abstract:
Prasugrel {systematic name: 5-[(2-cyclo-propyl-carbon-yl)(2-fluoro-phen-yl)meth-yl]-4,5,6,7-tetra-hydro-thieno[3,2-c]pyridin-2-yl acetate}, C(20)H(20)FNO(3)S, is a new third-generation thienopyridine which was recently approved for clinical use as a more potent blocker of the platelet P2Y(12) receptor than clopidogrel, which was previously used for this purpose. The mol-ecule features a tetra-hydro-thienopyridine system with the tetra-hydro-pyridine ring showing a half-chair conformation; the dihedral angle formed by the the planes of the benzene and thio-phene rings is 83.17 (3)°.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management
